Plain-English translation of NCT06340737 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing CD22 CAR T cells, a new immunotherapy treatment designed to fight B-cell lymphomas that have returned or stopped responding to prior treatments. Researchers take your own immune cells, engineer them in a laboratory to recognize and attack cancer cells, and then give them back to you. The trial will track how safe and effective this approach is for several types of B-cell lymphoma.
Many patients with B-cell lymphomas stop responding to standard treatments, and their cancer comes back or gets worse. This new treatment offers a different approach by harnessing your own immune system to fight the cancer, potentially helping patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will undergo a procedure called leukapheresis to collect your white blood cells, which are then sent to a laboratory to be engineered. While your cells are being prepared, you will receive chemotherapy to prepare your body. Once your engineered cells are ready, you will receive them back through an infusion. After that, you will have multiple follow-up visits and tests over time to monitor how well the treatment works, how you tolerate it, and whether your cancer responds.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States